Biogen's Phase 2 Data Shows Diranersen Slows Alzheimer’s Progression — Ionis Pharmaceuticals, Inc.

Event summary

Diranersen, an antisense oligonucleotide therapy targeting tau protein, demonstrated meaningful clinical outcomes in Biogen's Phase 2 CELIA study for early Alzheimer’s disease.
The 60 mg dose of diranersen showed the strongest response, slowing clinical decline by 26% on CDR-SB and achieving significant reductions in CSF total tau (50–65%).
Biogen plans to advance diranersen into Phase 3 development based on consistent evidence from Phase 1b and Phase 2 studies.
The study enrolled 416 participants with mild cognitive impairment or mild Alzheimer’s disease dementia, with no prior anti-amyloid therapy.

The big picture

The positive Phase 2 results for diranersen mark a significant step forward in the treatment of early Alzheimer’s disease, highlighting the potential of tau-directed therapies. This progress comes amid growing interest in RNA-targeted medicines and underscores Ionis Pharmaceuticals' expertise in developing innovative neurological treatments. The advancement into Phase 3 development will be closely watched as the field seeks effective interventions for this debilitating condition.

What we're watching

Clinical Efficacy: Whether the observed clinical benefits of diranersen will be sustained in Phase 3 trials and translate into long-term functional improvements.
Regulatory Pathway: The pace at which Biogen can secure regulatory approval for diranersen, given its Fast Track designation by the FDA.
Competitive Landscape: How diranersen’s tau-targeting mechanism differentiates it from other Alzheimer’s therapies in development and its potential market positioning.